Healthcare [ 4/11 ] | Biotechnology [ 50/148 ]
US | NASDAQ | Stock
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 16, 23 | 0.62 Increased by +127.56% | 0.29 Increased by +113.79% |
| May 18, 23 | -0.43 Increased by +62.61% | -0.54 Increased by +20.37% |
| May 15, 23 | -0.43 Increased by +62.61% | -0.54 Increased by +20.37% |
| Mar 31, 23 | -0.83 Increased by +63.11% | -0.85 Increased by +2.35% |
| Mar 21, 23 | -2.25 Increased by 0.00% | 1.38 Decreased by -263.04% |
| Nov 15, 22 | -1.15 Increased by +48.89% | -1.96 Increased by +41.33% |
| Nov 14, 22 | -1.15 Increased by +34.29% | -1.96 Increased by +41.33% |
| Aug 11, 22 | -2.25 Increased by +10.00% | -1.75 Decreased by -28.57% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 23 | 49.00 K Decreased by -97.88% | -12.92 M Increased by +43.90% | Decreased by -26.38 K% Decreased by -2.55 K% |
| Mar 31, 23 | 0.00 Decreased by -100.00% | -8.29 M Increased by +62.42% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 32.00 K Decreased by -99.42% | -12.40 M Decreased by N/A% | Decreased by -38.76 K% Decreased by N/A% |
| Sep 30, 22 | 65.00 K Increased by +1.26 K% | -10.63 M Decreased by N/A% | Decreased by -16.35 K% Decreased by N/A% |
| Jun 30, 22 | 2.32 M Increased by +N/A% | -23.04 M Decreased by -1.94% | Decreased by -994.73% Decreased by N/A% |
| Mar 31, 22 | 2.91 M Increased by +N/A% | -22.05 M Increased by +16.68% | Decreased by -757.35% Decreased by N/A% |
| Dec 31, 21 | 5.51 M Increased by +333.80% | 0.00 Increased by +100.00% | Increased by 0.00% Increased by +100.00% |
| Sep 30, 21 | 4.79 K Decreased by -94.43% | 0.00 Increased by +100.00% | Increased by 0.00% Increased by +100.00% |
Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as for acute respiratory distress syndrome, trauma complications, HSC transplant support, and other indications. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.